Chargement en cours...
Akt Inhibitors MK-2206 and Nelfinavir overcome mTOR inhibitor resistance in DLBCL
PURPOSE: The mTOR (mammalian Target of Rapamycin) pathway is constitutively activated in Diffuse Large B-Cell Lymphoma (DLBCL). mTOR inhibitors (mTORi) have activity in DLBCL, although response rates remain low. We evaluated DLBCL cell lines with differential resistance to the mTORi Rapamycin, in or...
Enregistré dans:
| Auteurs principaux: | , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
2012
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3889476/ https://ncbi.nlm.nih.gov/pubmed/22338016 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-11-1407 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|